Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767467 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
NCT01767467 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 568 participants.
The verdict
NCT01767467, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.
Interventions
- DRUG Placebo
- BIOLOGICAL Herpes zoster vaccine (GSK 1437173A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2017-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767467
The ClinicalTrials.gov registry entry for NCT01767467 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01767467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01767467 about?
NCT01767467 is a clinical study titled "Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers". The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo...
What is the current status of trial NCT01767467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2013-03-01. Estimated completion is 2017-01-06.
What interventions are being tested in trial NCT01767467?
The interventions under investigation include: Placebo (DRUG), Herpes zoster vaccine (GSK 1437173A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01767467?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.